PTC Therapeutics (PTCT) Misses Q1 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
May 3, 2022 4:01 PM EDT- $149 million total revenue representing impressive 26% year-over-year growth
- Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease
- CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch
SOUTH PLAINFIELD, N.J., May 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2022.
"We are continuing to build a robust... More
